It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
Sarat Sethi thinks investors should feed their portfolios food stocks. "We're putting money into food stocks, which are necessities, not discretionary items," the partner and portfolio manager for Douglas C. Lane and Associates told CNBC.
The world's biggest drug company is spending chump change to take out a little biotech at a 118 percent premium. Pfizer, which has a cash hoard of more than $20 billion, is plunking down a paltry (for Pfizer, that is) $195 million in cash money to buy Encysive Pharmaceuticals.
We ask the boss at Spam maker Hormel, why the stay-at-home eating trade is working?
European markets have recovered in the past two hours after a rough start. Credit Suisse roiled the markets early, as it announced $2.85 billion in writedowns -- just a few days after posting relatively strong fourth-quarter profit...
YouTube threw a coming out party of sorts to hundreds of top ad industry execs in New York City this week. The event was called 'Videocracy,' and it's the largest ever advertiser event thrown by Google which bought YouTube for $1.6 billion dollars two years ago.
U.S. stocks snapped a three-day losing streak Thursday, led by strong gains in the financial and retail sectors.
U.S. stocks turned firmly higher Thursday afternoon as bargain hunters scooped up undervalued stocks following three straight down days. Bank and retail stocks advanced. Even battered tech Cisco recovered.
U.S. stocks wavered Thursday as reports on January retail sales and jobless claims stirred recessionary fears. Tech stocks were under pressure after Cisco said consumers have become increasingly cautious. Retailers jumped.
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Most companies this morning reported disappointing earnings, and a few highlighted the impact of inflation on their bottom line. 1) Morgan Stanley reported a loss of $3.61 vs. a consensus of a loss of $0.39.
General Mills, Wednesday posted a 1 percent increase in quarterly profit, as higher sales were partially offset by more expensive marketing and a pizza recall.
Stocks staged a mini comeback Tuesday after a day that saw indexes seesaw on both sides of the unchanged line. The market once more fretted over the financial sector and could do the same on Wednesday.
Goldman Sachs (GS) is making a major shift in its analyst coverage, upgrading or downgrading 17 sectors on the fear of a softening economy. Could Goldman’s move be a bellwether of things to come? Or is it already late to the party?
Commodity inflation has become too much to handle for the food companies. Also, Cramer's take on the Merrill fallout and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Kellogg, the world's biggest maker of breakfast cereal, on Monday reported a 9 percent rise in quarterly earnings as increased sales and a weak dollar overshadowed higher prices for ingredients such as corn and milk.
A growing number of companies are embellishing their benefits packages with "concierge services" -- everything from flower deliveries and car detailing to restaurant reservations and clothes alterations.
Gilead Sciences posted a third-quarter profit that topped Wall Street targets on Thursday, on sales of drugs that fight the virus that causes AIDS, compared with a year-ago net loss due to acquisition- related costs.
There was a time within the past couple of years that it seemed you couldn't open a major newspaper or watch a TV news program without seeing a story about the bird flu and Tamiflu--the antiviral medicine from Roche and Gilead Sciences. GILD invented the drug and later sold rights to Roche which pays GILD a royalty on sales.
For quite some time now analysts and investors have been speculating that big pharma would go on a biotech buying binge. So, will the announcement by Biogen Idec late Friday that it's putting itself on the market be the spark that ignites an M & A explosion in the sector? Perhaps.